April 26th 2024
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
PD-L1 inhibitor plus chemo improves PFS for metastatic urothelial Ca
August 19th 2019Treatment combining the immunotherapy atezolizumab (Tecentriq) and platinum-based chemotherapy significantly improved progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma compared to chemotherapy alone.
Novel urothelial cancer Tx shows impressive response in phase II trial
July 15th 2019The novel antibody-drug conjugate enfortumab vedotin produced an impressive 44% response rate in a phase II trial of urothelial cancer patients who had been treated with standard chemotherapy and a checkpoint inhibitor.
Sense of urgency surrounds BCG shortage
June 12th 2019As urologists maneuver through the third shortage of bacillus Calmette-Guérin during the past decade, there is a sense of urgency to find short- and long-term alternative treatments to the only FDA-approved BCG strain as a therapeutic agent for nonmuscle-invasive bladder cancer.
Novel immunotherapy promising in BCG-unresponsive NMIBC
June 10th 2019The combination of an IL-15 cytokine agonist known as N-803 and bacillus Calmette–Guérin (BCG) was well tolerated and offered promising activity in patients with nonmuscle-invasive bladder cancer (NMIBC) who did not respond to BCG therapy, according to phase I and II study results.
Some MIBC patients could forgo cystectomy
August 28th 2018Findings of a multi-institutional cohort study provide further evidence that favorable outcomes can be achieved by carefully selected patients with muscle-invasive bladder cancer who forgo radical cystectomy after achieving a clinical complete response to neoadjuvant chemotherapy.
Sicker MIBC patients no more likely to undergo bladder sparing
August 14th 2018Even though patients with muscle-invasive bladder cancer and significant comorbidity are likely to benefit from bladder-sparing treatment approaches, increasing comorbidity burden appears to have no correlation with receiving such treatments.
Blue light flexible cysto deemed worthwhile by patients
August 14th 2018“I think this study indicates that this is a procedure that not only improves detection, but also has a high rate of perceived value for patients, and therefore would be worthwhile to use in practice,” says researcher Angela B. Smith, MD.